For chemotherapy the most effective dose is usually taken to be the most toxic one that is still acceptable, the maximum tolerated dose (MTD). For targeted and immune therapies the response may level off, or even fall, below the MTD, and the aim is then the optimal biological dose (OBD), which weighs the response against the toxicity. The BOIN-ET design of Takeda, Taguri and Morita (2018) decides the next dose from both the DLT rate and the response rate at the current dose, and selects the OBD at the end of the trial.
The package provides four designs of this family:
sim_boin_et() and sim_boin_et_multi();sim_tite_boin_et() and
sim_tite_boin_et_multi();sim_bf_boin_et() and
sim_bf_boin_et_multi();sim_boin_etc() and
sim_boin_etc_multi().The rules follow the R packages of the authors, ‘boinet’ (Yamaguchi, Takeda and Maruo, 2025) for the first two and ‘bfboinet’ for the third, with the changes described below, and the article for BOIN-ETC, with the rules of the code of the authors as options. The trials and the selection of the OBD run in C++.
The DLT rate at the current dose is compared with two boundaries,
lambda1 and lambda2, and the response rate
with one, eta1. They minimize the probability of an
incorrect decision, as found by the grid search of
boinet::gridoptim().
bd <- boin_et_boundary(target = 0.30, target_resp = 0.60)
bd
#> BOIN-ET boundaries
#> target DLT rate : 0.3
#> target response rate : 0.6
#> p_saf / p_tox : 0.03 / 0.42
#> p_saf_resp : 0.36
#>
#> lambda1 (escalate) : 0.14
#> lambda2 (de-escalate): 0.35
#> eta1 (response) : 0.48
#> probability of an incorrect decision: 0.04703With a target DLT rate of 0.30, a target response rate of 0.60 and
the design parameters of Takeda et al. (2018), the boundaries are 0.14
for lambda1, 0.35 for lambda2 and 0.48 for
eta1, the values of the article. The decision at the
current dose is then
lambda1 and the response rate at most
eta1;lambda2 and the response rate above eta1;lambda2;boin_et_decision_table(target = 0.30, target_resp = 0.60, n = c(3, 6))
#> BOIN-ET decision table
#> lambda1 = 0.14, lambda2 = 0.35, eta1 = 0.48
#>
#> 3 patients
#> Responses
#> DLTs 0 1 2 3
#> 0 E E S S
#> 1 E/S/D E/S/D S S
#> 2 D D D D
#> 3 D* D* D* D*
#>
#> 6 patients
#> Responses
#> DLTs 0 1 2 3 4 5 6
#> 0 E E E S S S S
#> 1 E/S/D E/S/D E/S/D S S S S
#> 2 E/S/D E/S/D E/S/D S S S S
#> 3 D D D D D D D
#> 4 D* D* D* D* D* D* D*
#> 5 D* D* D* D* D* D* D*
#> 6 D* D* D* D* D* D* D*
#>
#> E = escalate, S = stay, D = de-escalate, E/S/D = choose among the current and neighboring doses;
#> * = the dose is no longer admissibleThese are the decisions of Table 2 of Takeda et al. (2018). A star
marks the counts that make a dose inadmissible: by default, as in
‘boinet’, a dose is excluded when the posterior probability that its DLT
rate exceeds target is above
cutoff_eli = 0.95, or when the posterior probability that
its response rate is below p_saf_resp is above
cutoff_eli_resp = 0.99. p_eli and
p_eli_resp change the two rates; the simulations of the
article exclude a dose when the posterior probability that its DLT rate
is below 0.40 is less than 0.10, or that its response rate is above 0.20
is less than 0.10 (p_eli = 0.40,
p_eli_resp = 0.20, cutoff_eli = 0.90 and
cutoff_eli_resp = 0.90).
Scenario 1 of Takeda et al. (2018) has six doses, twelve cohorts of three patients and a trial that starts at the lowest dose.
p_true <- c(0.05, 0.15, 0.25, 0.30, 0.35, 0.40)
p_resp <- c(0.05, 0.35, 0.55, 0.65, 0.75, 0.70)
oc <- sim_boin_et(target = 0.30, target_resp = 0.60, p_true = p_true,
p_resp = p_resp, n_cohort = 12, cohort_size = 3,
n_trials = 2000, seed = 123)
oc
#> BOIN-ET operating characteristics
#> target DLT rate : 0.3
#> target response rate : 0.6
#> trials : 2000
#> cohorts : 12 of size 3
#> max sample size : 36
#> lambda1 / lambda2 : 0.14 / 0.35
#> eta1 : 0.48
#> OBD selection : max_resp with observed response rates
#>
#> DL1 DL2 DL3 DL4 DL5 DL6 Total / No OBD
#> True DLT rate (%) 5.0 15.0 25.0 30.0 35.0 40.0
#> True response rate (%) 5.0 35.0 55.0 65.0 75.0 70.0
#> OBD selected (%) 1.5 16.1 47.1 26.7 7.0 0.5 1.1
#> Patients treated 3.5 8.9 14.3 7.1 1.8 0.2 35.8
#> Patients with DLT 0.2 1.3 3.6 2.2 0.6 0.1 8.0
#> Patients with response 0.2 3.1 7.9 4.7 1.4 0.1 17.3
#>
#> Trials stopped early: 1.1%The output gives the percentage of trials selecting each dose as the OBD, the average numbers of patients, DLTs and responses at each dose, and the percentage of trials stopped early. Here dose 3 is selected most often, in 47 percent of the trials, and 1.1 percent of the trials select no OBD.
Several scenarios are run with sim_boin_et_multi(). In
scenario 7 of the article the response rate peaks at dose 2 while the
DLT rate goes on rising.
scenarios <- list(
list(name = "Scenario 1", p_true = p_true, p_resp = p_resp),
list(name = "Scenario 7", p_true = c(0.05, 0.15, 0.25, 0.35, 0.45, 0.55),
p_resp = c(0.30, 0.70, 0.60, 0.50, 0.40, 0.30))
)
sim_boin_et_multi(target = 0.30, target_resp = 0.60, scenarios = scenarios,
n_cohort = 12, cohort_size = 3, n_trials = 1000,
seed = 123)
#> BOIN-ET operating characteristics across 2 scenarios
#> target DLT rate : 0.3
#> target response rate : 0.6
#> trials each : 1000
#> max sample size : 36
#> OBD selection : max_resp with observed response rates
#>
#> Scenario Item DL1 DL2 DL3 DL4 DL5 DL6 Total / No OBD
#> Scenario 1 True DLT rate (%) 5.0 15.0 25.0 30.0 35.0 40.0
#> True response rate (%) 5.0 35.0 55.0 65.0 75.0 70.0
#> OBD selected (%) 1.7 17.0 47.4 26.5 6.1 0.3 1.0
#> Patients treated 3.5 9.1 14.4 7.0 1.7 0.2 35.9
#> Patients with DLT 0.2 1.4 3.6 2.2 0.6 0.1 8.0
#> Patients with response 0.2 3.1 7.9 4.6 1.2 0.1 17.3
#> Scenario 7 True DLT rate (%) 5.0 15.0 25.0 35.0 45.0 55.0
#> True response rate (%) 30.0 70.0 60.0 50.0 40.0 30.0
#> OBD selected (%) 3.0 80.8 12.1 3.3 0.7 0.0 0.1
#> Patients treated 5.6 25.5 3.4 1.1 0.4 0.1 36.0
#> Patients with DLT 0.3 3.9 0.8 0.4 0.1 0.1 5.6
#> Patients with response 1.7 17.8 2.1 0.6 0.1 0.0 22.3At the end of a trial the DLT rates of the doses tried are made
monotone by isotonic regression, and the response rates are estimated
with one of three estimators (est_method): the observed
rates (the default), the model-averaged unimodal isotonic regression of
Lin and Yin (2017) ("multi_iso"), or the fractional
polynomial logistic regression of Takeda et al. (2018)
("fp_logistic", which needs the ‘mfp’ package). The OBD is
then chosen among the admissible doses with one of four rules
(obd_method): the highest estimated response rate up to the
estimated MTD ("max_resp", the default), or the highest
value of one of the three utilities compared by Yamaguchi et al. (2024)
("utility_weighted",
"utility_truncated_linear" and
"utility_scoring").
boin_et_select_obd() selects the OBD from the final data
of trials, so the same simulated trials can be judged under every
rule.
oc_kept <- sim_boin_et(target = 0.30, target_resp = 0.60, p_true = p_true,
p_resp = p_resp, n_cohort = 12, cohort_size = 3,
n_trials = 2000, keep_trials = TRUE, seed = 123)
tr <- oc_kept$trials
select_percent <- function(est_method, obd_method) {
obd <- boin_et_select_obd(n_pts = tr$n_pts, n_tox = tr$n_tox,
n_resp = tr$n_resp, target = 0.30,
target_resp = 0.60, est_method = est_method,
obd_method = obd_method,
early_stop = tr$early_stop)$obd
as.numeric(table(factor(obd, levels = 1:6))) / length(obd) * 100
}
rules <- c("max_resp", "utility_weighted", "utility_truncated_linear",
"utility_scoring")
selection <- rbind(
t(sapply(rules, function(m) select_percent("observed", m))),
"max_resp, multi_iso" = select_percent("multi_iso", "max_resp")
)
colnames(selection) <- paste0("DL", 1:6)
round(selection, 1)
#> DL1 DL2 DL3 DL4 DL5 DL6
#> max_resp 1.5 16.1 47.1 26.7 7.0 0.5
#> utility_weighted 1.5 16.4 44.0 28.5 7.6 0.8
#> utility_truncated_linear 5.9 34.3 39.1 15.7 3.3 0.4
#> utility_scoring 2.1 16.6 39.4 29.8 10.1 1.0
#> max_resp, multi_iso 0.2 14.4 48.9 27.7 7.0 0.5
all.equal(unname(selection["max_resp", ]), unname(oc_kept$sel_percent))
#> [1] TRUEThe first row is the selection of sim_boin_et(), which
calls boin_et_select_obd() with the same defaults. The
fractional polynomial is fitted once for every distinct set of final
data and takes longer:
After each cohort the admissibility of every dose is derived again from its data, and the trial stops early when no dose is admissible, or when the dose should be lowered and no admissible dose is found at or below the intended one. When the intended dose is not admissible, a stay or a de-escalation moves to the highest admissible dose below it, and an escalation to the lowest admissible dose above it, or stays when there is none.
Two rules differ from those of ‘boinet’ 1.6.0. Takeda et al. (2018)
do not allow dose skipping during escalation, so a dose excluded by its
DLT data also excludes every higher dose, as in the later BF-BOIN-ET
design and the ‘bfboinet’ package, and an escalation from the highest
dose ends the trial when that dose is excluded. In ‘boinet’, an
escalation can skip a dose excluded by its DLT data and reach an untried
higher dose, and an escalation from the highest dose stays there even
when it is excluded. boinet_compatible = TRUE applies these
rules of ‘boinet’ in every BOIN-ET and TITE-BOIN-ET function.
skip_design <- list(target = 0.30, target_resp = 0.60,
p_true = c(0.10, 0.20, 0.45, 0.50, 0.55),
p_resp = c(0.10, 0.20, 0.30, 0.50, 0.60),
n_cohort = 12, cohort_size = 3, n_trials = 2000,
seed = 123)
oc_default <- do.call(sim_boin_et, skip_design)
oc_boinet <- do.call(sim_boin_et,
c(skip_design, list(boinet_compatible = TRUE)))
round(rbind(default = oc_default$n_pts_dose,
boinet = oc_boinet$n_pts_dose), 2)
#> DL1 DL2 DL3 DL4 DL5
#> default 5.20 14.65 9.73 4.77 1.13
#> boinet 4.84 11.57 9.47 6.89 3.05Doses 4 and 5, with DLT probabilities of 0.50 and 0.55, receive 5.9 patients per trial on average under the default rules and 9.9 under those of ‘boinet’, which let an escalation from dose 2 skip dose 3 once it is excluded.
When the DLT and the response take long to assess compared with the time between arrivals, TITE-BOIN-ET doses new patients while earlier ones are still assessed. A patient still under assessment counts in the DLT and response rates of a dose by the fraction of the window followed so far (Takeda et al., 2020), and the decision rule of BOIN-ET is applied to these rates. The admissibility of the doses counts such a patient as a patient without the event, as in ‘boinet’.
The first patient of a cohort arrives at the time of the previous
decision, and the next decision is due when the next patient arrives.
While fewer than a share min_completed_share of the
patients at the current dose have finished both assessments, the
decision waits for the next assessment to end. The default, 0.5, is the
rule of boinet::tite.boinet(). The simulations of Takeda et
al. (2020) did not wait (min_completed_share = 0), and the
article recommends such a rule when the accrual is fast. By default the
times to DLT and to response are Weibull, with
late_fraction and resp_late_fraction of the
events in the second half of each window, and they are linked by a
Gaussian copula with correlation resp_cor.
The setting of Takeda et al. (2020) is a DLT window of 28 days, a response window of 56 days and one patient every 14 days; the unit of time is the day.
tite_design <- list(target = 0.30, target_resp = 0.60, p_true = p_true,
p_resp = p_resp, n_cohort = 12, cohort_size = 3,
window = 28, resp_window = 56, accrual_rate = 1 / 14,
n_trials = 1000, seed = 123)
oc_tite <- do.call(sim_tite_boin_et, tite_design)
oc_tite
#> TITE-BOIN-ET operating characteristics
#> target DLT rate : 0.3
#> target response rate : 0.6
#> trials : 1000
#> cohorts : 12 of size 3
#> max sample size : 36
#> lambda1 / lambda2 : 0.14 / 0.35
#> eta1 : 0.48
#> OBD selection : max_resp with observed response rates
#>
#> DL1 DL2 DL3 DL4 DL5 DL6 Total / No OBD
#> True DLT rate (%) 5.0 15.0 25.0 30.0 35.0 40.0
#> True response rate (%) 5.0 35.0 55.0 65.0 75.0 70.0
#> OBD selected (%) 1.1 18.0 44.8 26.9 6.1 0.4 2.7
#> Patients treated 4.0 9.3 13.5 6.9 1.8 0.2 35.6
#> Patients with DLT 0.2 1.5 3.4 2.1 0.7 0.1 7.9
#> Patients with response 0.2 3.2 7.4 4.5 1.4 0.2 16.9
#>
#> Trials stopped early: 2.7%
#> Average trial duration: 616.5
oc_tite_0 <- do.call(sim_tite_boin_et,
c(tite_design, list(min_completed_share = 0)))
round(rbind(
"wait for half" = c(oc_tite$sel_percent, weeks = oc_tite$duration / 7),
"no wait" = c(oc_tite_0$sel_percent, weeks = oc_tite_0$duration / 7)
), 1)
#> DL1 DL2 DL3 DL4 DL5 DL6 weeks
#> wait for half 1.1 18.0 44.8 26.9 6.1 0.4 88.1
#> no wait 0.9 20.7 45.6 23.0 7.2 0.3 77.1The trials last 88 weeks on average with the default rule and 77 weeks without waiting. The duration runs from the arrival of the first patient to the last decision, which is the end of both assessments of every patient when all cohorts are enrolled. The durations reported by Takeda et al. (2020) correspond to counting also the interval between arrivals before the first patient.
In BF-BOIN-ET a cohort is treated at the current dose, and the next
cohort starts with the first patient who arrives once the DLT outcomes
of the cohort are known. The patients who arrive in between are
backfilled one by one, when the current dose is not the lowest, to the
lower dose with the highest utility among those with a promising
response rate. The utility is defined by the scores psi00,
psi_dlt_no_resp, psi_resp_no_dlt and
psi11 of a patient without DLT or response, with a DLT
only, with a response only and with both. The dose escalation uses the
DLT rate at the current dose with the boundaries of BOIN, and stays
after 1 DLT in 3 patients. A dose with n_elimination
patients or more is excluded for good when its DLT or response data are
poor, a dose excluded by its DLT data taking every higher dose with it.
The OBD is the admissible dose up to the estimated MTD with the highest
utility. The rules are those of
bfboinet::get.oc.backboinet().
The example of ‘bfboinet’ has five doses, ten cohorts of three, windows of one month and three patients a month; the unit of time is the month.
bf_design <- list(target = 0.30, target_resp = 0.25,
p_true = c(0.03, 0.05, 0.20, 0.22, 0.45),
p_resp = c(0.05, 0.10, 0.50, 0.68, 0.70),
n_cohort = 10, cohort_size = 3, window = 1,
accrual_rate = 3, n_trials = 1000, seed = 123)
oc_bf <- do.call(sim_bf_boin_et, bf_design)
oc_bf
#> BF-BOIN-ET operating characteristics
#> target DLT rate : 0.3
#> target response rate : 0.25
#> trials : 1000
#> cohorts : 10 of size 3
#> patients per dose : 12 at most with backfill
#> lambda1 / lambda2 : 0.2365 / 0.3585
#> eta1 : 0.1968
#>
#> DL1 DL2 DL3 DL4 DL5 Total / No OBD
#> True DLT rate (%) 3.0 5.0 20.0 22.0 45.0
#> True response rate (%) 5.0 10.0 50.0 68.0 70.0
#> OBD selected (%) 2.2 3.5 40.7 48.0 5.5 0.1
#> Patients treated 4.1 5.9 11.3 9.8 5.3 36.3
#> Patients backfilled 0.7 1.4 4.5 2.8 0.2 9.5
#> Patients with DLT 0.1 0.3 2.2 2.1 2.4 7.2
#> Patients with response 0.2 0.6 5.6 6.6 3.7 16.7
#>
#> Trials stopped early: 0%
#> Average trial duration: 16.8With suspend = 0.33 the next cohort may start while a
third of the patients at the current dose are still assessed for DLT,
which is the BF-BOIN-ET-A design of Takeda et al. (2025); the default,
suspend = 0, is their BF-BOIN-ET-C design.
oc_bf_a <- do.call(sim_bf_boin_et, c(bf_design, list(suspend = 0.33)))
round(rbind(
"BF-BOIN-ET-C" = c(oc_bf$sel_percent, patients = oc_bf$total_n_pts,
backfilled = oc_bf$total_n_bf,
months = oc_bf$duration),
"BF-BOIN-ET-A" = c(oc_bf_a$sel_percent, patients = oc_bf_a$total_n_pts,
backfilled = oc_bf_a$total_n_bf,
months = oc_bf_a$duration)
), 1)
#> DL1 DL2 DL3 DL4 DL5 patients backfilled months
#> BF-BOIN-ET-C 2.2 3.5 40.7 48.0 5.5 36.3 9.5 16.8
#> BF-BOIN-ET-A 3.2 3.5 40.8 45.5 6.2 33.6 6.1 13.3The patients include the backfilled ones. The trials last 16.8 months on average under BF-BOIN-ET-C and 13.3 months under BF-BOIN-ET-A.
When two drugs are given together, the doses form a matrix, with the
L levels of drug A in the rows and the M
levels of drug B in the columns. BOIN-ETC (Kakizume et al., 2024)
divides the matrix into subtrials along which the DLT rate increases and
runs the rules of BOIN-ET in each of them, from its lowest combination.
A subtrial ends when the combination chosen for the next cohort already
has n_earlystop patients (6 by default, n_stop
of the article), and that combination is the candidate of the subtrial.
The first subtrial goes up drug A at the lowest level of drug B and then
along the highest level of drug A,
A1B1, A2B1, ..., ALB1, ALB2, ..., ALBM. The three versions
then differ (subtrials):
"etc1", the default) and
BOIN-ETC2 ("etc2") run one subtrial per
level of drug A, from level L - 1 down to level 1, over
levels 2 to M of drug B; when the candidate of the first
subtrial is at level l of drug A and level 1 of drug B,
they start at level l - 1 of drug A. BOIN-ETC2 starts every
subtrial at level 2 of drug B. BOIN-ETC1 starts it next to the candidate
of the previous subtrial, and the article and its code differ there: the
text and the figures start one level of drug B lower, diagonally below
the candidate (etc1_start = "diagonal", the default), and
the code of the authors at the same level of drug B, directly below it
(etc1_start = "below"), in both cases at level 2 or
above."etc3") runs L-shaped
subtrials: the subtrial j goes up level j + 1
of drug B to level L - j of drug A and then along that
level of drug A to level M of drug B.The names follow the figures, the tables and the code of the article;
the text of its Section 2.2 describes BOIN-ETC2 and BOIN-ETC3 the other
way round. A combination is excluded when the posterior probability that
its DLT rate exceeds target is above
cutoff_eli = 0.95, and with it the higher combinations of
its subtrial; the subtrial ends when its lowest combination is excluded,
and the trial ends when that combination is A1B1. In the code of the
authors, the choice among the neighboring combinations when the decision
of BOIN-ET is E/S/D moves one combination down when the combination
below the current one is untreated; rule4 = "authors_code"
applies this rule, and rule4 = "paper", the default, the
rule of the text. Only etc1_start = "below" with
rule4 = "authors_code" reproduces the allocation published
for BOIN-ETC1.
At the end of the trial the DLT rates are made monotone along both
drugs by bivariate isotonic regression, the MTD combination of every
level of drug A bounds the candidates of that level, and the optimal
dose combination (ODC) is the treated, not excluded candidate with the
highest posterior mean of the utility of BOIN12, with the scores
psi00 and psi11 (40 and 60 by default).
boin_etc_select_obd() applies this selection to completed
trials. When candidates tie, odc_tie = "lowest" (the
default) selects the lowest one, and odc_tie = "all" counts
every tied candidate, as the percentages of the article do.
Scenario 1 of the article has two levels of drug A, three of drug B, a target DLT rate of 0.30, a target response rate of 0.60 and at most 24 patients.
p_true_ab <- matrix(c(0.05, 0.10, 0.10, 0.30, 0.30, 0.50), nrow = 2)
p_resp_ab <- matrix(c(0.10, 0.25, 0.25, 0.60, 0.60, 0.65), nrow = 2)
oc_etc <- sim_boin_etc(target = 0.30, target_resp = 0.60, p_true = p_true_ab,
p_resp = p_resp_ab, n_cohort = 8, cohort_size = 3,
n_trials = 2000, seed = 123)
oc_etc
#> BOIN-ETC1 operating characteristics
#> target DLT rate : 0.3
#> target response rate : 0.6
#> dose levels : 2 of drug A, 3 of drug B
#> trials : 2000
#> cohorts : 8 of size 3
#> max sample size : 24
#> subtrial end (n_stop): 6
#> lambda1/lambda2/eta1 : 0.14 / 0.35 / 0.48
#> start of a row : diagonal
#> rule 4 : paper
#> utility scores : 100, 40, 60, 0; ties lowest
#>
#> Item Drug A B1 B2 B3
#> True DLT rate (%) A1 5.0 10.0 30.0
#> A2 10.0 30.0 50.0
#> True response rate (%) A1 10.0 25.0 60.0
#> A2 25.0 60.0 65.0
#> OBD selected (%) A1 3.4 11.3 31.3
#> A2 13.7 36.4 3.9
#> Patients treated A1 3.2 4.2 4.5
#> A2 4.3 4.9 1.3
#> Patients with DLT A1 0.2 0.4 1.3
#> A2 0.4 1.5 0.6
#> Patients with response A1 0.3 1.0 2.7
#> A2 1.1 3.0 0.8
#>
#> No OBD selected : 0%
#> Trials stopped early : 0%
#> Average number of patients : 22.3
#> Average number of subtrials : 2
#>
#> True OBD (highest true utility) : A2B2, A1B3
#> Selected as the OBD : 67.8%
#> Patients treated there : 42.1%
#> Combinations above the target DLT : 1 of 6
#> Selected as the OBD : 3.9%
#> Patients treated there : 5.7%The true ODCs, the combinations with the highest utility among those with a DLT rate at most 0.30, are A2B2, A1B3. The three versions, and BOIN-ETC1 with the rules of the code of the authors, compare as follows, with tied ODCs counted as in the article:
etc_versions <- list(
"BOIN-ETC1" = list(subtrials = "etc1"),
"BOIN-ETC1, code" = list(subtrials = "etc1", etc1_start = "below",
rule4 = "authors_code"),
"BOIN-ETC2" = list(subtrials = "etc2"),
"BOIN-ETC3" = list(subtrials = "etc3")
)
etc_runs <- lapply(etc_versions, function(v) {
do.call(sim_boin_etc,
c(list(target = 0.30, target_resp = 0.60, p_true = p_true_ab,
p_resp = p_resp_ab, n_cohort = 8, cohort_size = 3,
n_trials = 2000, odc_tie = "all", seed = 123), v))
})
round(t(sapply(etc_runs, function(o) {
c("ODC selected (%)" = o$pct_true_obd_selected,
"Patients at ODC (%)" = o$pct_patients_true_obd,
"Patients" = o$total_n_pts, "Subtrials" = o$mean_subtrials)
})), 1)
#> ODC selected (%) Patients at ODC (%) Patients Subtrials
#> BOIN-ETC1 73.4 42.1 22.3 2
#> BOIN-ETC1, code 75.1 42.7 22.3 2
#> BOIN-ETC2 73.4 42.1 22.3 2
#> BOIN-ETC3 73.4 42.1 22.3 2The scripts in inst/reproduce/ and
inst/validation/ compare the package with the articles and
with the packages and the code of the authors, and write the tables of
judgments in their results/ folders, which are summarized
here. A simulated cell passes when it lies within four standard errors
of the difference between the two simulations plus the rounding of the
published value.
sim_boin_et() and sim_tite_boin_et() with
boinet_compatible = TRUE are compared with those of
boinet::boinet() and boinet::tite.boinet():
312 of 312 cells pass for BOIN-ET and 196 of 196 for TITE-BOIN-ET. The
packages draw their random numbers differently, so they agree in
distribution, not trial by trial. The tests also compare the boundaries
with boinet::gridoptim() and the OBD of simulated trials
with boinet::obd.select() exactly.sim_bf_boin_et() with
bfboinet::get.oc.backboinet() pass.etc1_start = "below" and
rule4 = "authors_code" for BOIN-ETC1, 1168 of the 1176
values of the allocation (the mean numbers of patients at every
combination of Supplementary Tables S4 and S5, and %nODC and #N of Table
3 and Supplementary Tables S1 and S6 to S9) pass, and the 8 others are
misprints that disagree with the other tables of the article. The 996
values of the selection (%ODC and Supplementary Tables S2 and S3) are
listed for information, because the code of the authors estimates the
DLT rates with Iso::biviso(), whose convergence errors
decide between the combinations that tie for the MTD combination of a
level of drug A in the exact isotonic regression of the package; 982 of
them lie within the tolerance.inst/validation/compare-with-BOINETC.R runs the R code of
the authors. With the random numbers of R after
set.seed(1234) it gives 1657 of the 1692 published values
of the allocation and the selection of Scenarios 1 to 5 and 7 to 9 to
the printed digits, and the 35 others are misprints. On the same trials,
boin_etc_select_obd() selects other combinations than the
code in 4.6 percent of the trials on average, because combinations tie
for the MTD combination of a level of drug A in the exact isotonic
regression or because the code selects an untreated or excluded
combination; no trial differs for another reason.Takeda, K., Taguri, M. and Morita, S. (2018). BOIN-ET: Bayesian optimal interval design for dose finding based on both efficacy and toxicity outcomes. Pharmaceutical Statistics, 17(4), 383-395.
Takeda, K., Morita, S. and Taguri, M. (2020). TITE-BOIN-ET: Time-to-event Bayesian optimal interval design to accelerate dose-finding based on both efficacy and toxicity outcomes. Pharmaceutical Statistics, 19(3), 335-349.
Takeda, K., Zhu, J. and Hirakawa, A. (2025). BF-BOIN-ET: A backfill Bayesian optimal interval design using efficacy and toxicity outcomes for dose optimization. Pharmaceutical Statistics, 24(2), e2470.
Yamaguchi, Y., Takeda, K. and Maruo, K. (2025). boinet: An R package for Bayesian optimal interval design for dose finding based on both efficacy and toxicity outcomes. The R Journal, 17(2), 15-34.
Yamaguchi, Y., Takeda, K., Yoshida, S. and Maruo, K. (2024). Optimal biological dose selection in dose-finding trials with model-assisted designs based on efficacy and toxicity: a simulation study. Journal of Biopharmaceutical Statistics, 34(3), 379-393.
Kakizume, T., Takeda, K., Taguri, M. and Morita, S. (2024). BOIN-ETC: A Bayesian optimal interval design considering efficacy and toxicity to identify the optimal dose combinations. Statistical Methods in Medical Research, 33(4), 716-727.
Lin, R. and Yin, G. (2017). STEIN: A simple toxicity and efficacy interval design for seamless phase I/II clinical trials. Statistics in Medicine, 36(26), 4106-4120.